Report: Merck Analyst Report: Mylan Technologies MYL Analyst Report: Teva Pharmaceuticals Analyst Report: Watson Pharmaceuticals WPI Rethinking Title Insurer Moat, Risk Ratings Analyst Jim Ryan reduced the moat rating and increased the risk
Now trading under its official new name, Actavis ACT (formerly Watson Pharmaceuticals ) highlighted its long-term growth strategy and presented expectations for the current quarter and upcoming 2013 results at its
Pharmaceuticals declined despite reporting earnings above expectations, and a resolution of pending litigation with Watson Pharmaceuticals regarding Endo’s Lidoderm. Investors are concerned about the potential for generic competition for Endo’s
the firm’s former flagship product beginning in late 2013, which is the earliest that generic drugmaker Watson Pharmaceuticals WPI will be able to launch its authorized generic version of the pain patch. We think Opana ER could help offset
June 27 - Fitch Ratings has assigned a 'BBB' rating to Watson Pharmaceuticals , Inc .'s (Watson) (NYSE: WPI) new five-year senior unsecured term loan facility with an aggregate principal amount of $1
or ANDA, for a generic version of the drug filed by Actavis (which is in the process of being acquired by Watson Pharmaceuticals WPI ). Shire previously authorized two branded generic versions of Adderall XR, through Teva TEVA and Impax
Endo Pharmaceuticals ENDP announced that it has reached an agreement with generic drugmaker Watson Pharmaceuticals WPI regarding marketing exclusivity for its pain patch Lidoderm. The settlement removes a great deal of uncertainty surrounding the
Watson Pharmaceuticals WPI reported first-quarter results that mostly met our expectations. However, as a result of the Actavis acquisition announced
(Reuters) - Generic drugmaker Watson Pharmaceuticals Inc said U.S. health regulators approved its copycat version of ViroPharma Inc's antibiotic Vancocin.
(Reuters) - Shares of Watson Pharmaceuticals Inc rose more than 5 percent on Thursday, extending their gains on optimism over benefits from a possible acquisition of rival generic drugmaker Actavis.